Head-To-Head Analysis: Novartis (NYSE:NVS) and Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ:INVA – Get Free Report) and Novartis (NYSE:NVS – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Innoviva and Novartis”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innoviva $438.32 million 3.00 $271.17 million $1.99 9.29
Novartis $54.53 billion 5.60 $13.98 billion $5.24 30.54

Novartis has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.1% of Innoviva shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Innoviva has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Innoviva and Novartis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innoviva 44.13% 22.91% 16.67%
Novartis 18.11% 41.04% 14.45%

Analyst Recommendations

This is a summary of current ratings for Innoviva and Novartis, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innoviva 0 1 5 0 2.83
Novartis 3 9 6 0 2.17

Innoviva currently has a consensus target price of $39.00, suggesting a potential upside of 110.92%. Novartis has a consensus target price of $152.25, suggesting a potential downside of 4.86%. Given Innoviva’s stronger consensus rating and higher possible upside, equities analysts clearly believe Innoviva is more favorable than Novartis.

Summary

Novartis beats Innoviva on 8 of the 14 factors compared between the two stocks.

About Innoviva

(Get Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

About Novartis

(Get Free Report)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.